Trial Profile
To compare the efficacy and safety of apixaban, rivaroxaban and dabigatran in patients with atrial fibrillation: a retrospective, cohort study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions; Therapeutic Use
- 03 Dec 2018 New trial record
- 13 Nov 2018 Results published in the British Journal of Clinical Pharmacology